Skip to main content
Caplight Logo









GC Therapeutics

GC Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.gc-tx.com/

Last Round

Series A

Sep 19, 2024

Total Funding Raised

$85M

Company Overview

GC Therapeutics is a biotechnology company that specializes in programming patient-derived stem cells into various cell types using an innovative platform that combines synthetic biology and artificial intelligence to create advanced cell therapies with enhanced manufacturing efficiency and quality.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cell therapystem cell differentiationregenerative medicineTFomesynthetic biologybiotech platformcell fate programmingmachine learning in biologydrug discoverybiomanufacturingcell therapy manufacturingai-native biotechbiofoundrycell engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GC Therapeutics Comparables

Compare GC Therapeutics with similar companies based on industry and business-model similarity.

GC Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Syntax Bio
88%
Trailhead Biosystems Inc.
82%
Mogrify
82%

GC Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 19, 2024

Key People

Founding team and executive leadership

Parastoo Khoshakhlagh

CEO & Co-Founder

Founding Team

GC Therapeutics Investors

Notable investors and investment history

GC Therapeutics investors
InvestorRounds
Andreessen HorowitzSeries A, Seed
Cormorant Asset ManagementSeries A
GaingelsSeries A
Global Brain CorporationSeries A
Medical Excellence CapitalSeries A
Pear VCSeries A
Mubadala CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2026

    Kate Haviland appointed as new board chair.

  • Apr 1, 2025

    Proprietary TFome™ platform developed in Professor George Church's lab.

GC Therapeutics Filings

Explore SEC and related filing metadata, where available.

GC Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GC Therapeutics's valuation, stock price, and market status.

Is GCTx a public or private company?

GCTx is a private company.

What is the current stock price of GCTx?

GCTx is a private company with no public stock price. No recent secondary market data is available.

How much is GCTx worth (valuation)?

Valuation information for GCTx is not publicly available.

Can I buy GCTx stock?

GCTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GCTx's last funding round?

GCTx's most recent funding round was Series A on September 19, 2024.

Who are the main investors in GCTx?

Key investors in GCTx include Cormorant Asset Management.

Will GCTx IPO soon?

No public IPO plans have been announced for GCTx.

How can I track GCTx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GCTx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range44
Year Founded2019
Last FundingSep 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?